Cargando…
Expression, Localization and Prognosis Association of MEP50 in Breast Cancer
SIMPLE SUMMARY: The arginine methyltransferase PRMT5 is an emerging therapeutic target for various cancers including breast cancer. In this study, we examine the expression and subcellular localization of its main cofactor, MEP50, in the different breast cancer subgroups. High levels of MEP50 are fo...
Autores principales: | Suresh, Samyuktha, Vinet, Mathilde, Dakroub, Rayan, Lesage, Laetitia, Ye, Mengliang, Fayyad-Kazan, Hussein, Nicolas, André, Meseure, Didier, Dubois, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563057/ https://www.ncbi.nlm.nih.gov/pubmed/36230689 http://dx.doi.org/10.3390/cancers14194766 |
Ejemplares similares
-
Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
por: Dakroub, Rayan, et al.
Publicado: (2023) -
PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer
por: Suresh, Samyuktha, et al.
Publicado: (2022) -
Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers
por: Vinet, Mathilde, et al.
Publicado: (2019) -
Biopathological Significance of PIWI–piRNA Pathway Deregulation in Invasive Breast Carcinomas
por: Meseure, Didier, et al.
Publicado: (2020) -
In Vitro Influence of Prophylaxis Cleaning on Enamel Remineralization with Casein Phosphopeptide-Amorphous Calcium Phosphate
por: Zeitouny, Mona, et al.
Publicado: (2020)